- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
High Risks, High Costs Associated With Febrile Neutropenia in Metastatic Cancer
Data from 2 large studies of patients with metastatic disease who underwent myelosuppressive chemotherapy found that febrile neutropenia occurred in approximately 13% to 21% of patients. Associated costs of febrile neutropenia were found to range from $16,000 to $19,000 per episode for most hospitalized patients.
Neutropenia is a common complication in patients receiving myelosuppressive chemotherapy that leaves them vulnerable to infectious diseases. Data from 2 large studies of a broad group of over 15,300 patients with metastatic disease who underwent myelosuppressive chemotherapy found that febrile neutropenia occurred in approximately 13% to 21% of patients throughout their course of chemotherapy, typically during their first cycle. The study was published in the Journal of Oncology Practice.
High rates of febrile neutropenia were found in patients with lung and prostate cancers; those with ovarian and colorectal cancers had a lower incidence of febrile neutropenia.
“Overall, for a wide variety of metastatic solid tumors, febrile neutropenia remains a common and adverse effect of myelosuppressive chemotherapy with significant mortality and high economic burden,” the study concluded
The researchers, led by Derek Weycker, PhD, senior health economist at Policy Analysis, Inc, in Brookline, MA, used data from 2006 to 2011 from a large health care claims data base of adult patients who underwent myelosuppressive chemotherapy for one of five major solid tumors: lung cancer, prostate cancer, breast cancer, colorectal cancer, and ovarian cancer.
“Febrile neutropenia was found to be a frequent complication among patients receiving myelosuppressive chemotherapy for metastatic solid tumors in U.S. clinical practice, and among the subset of patients who had a febrile neutropenia episode, the clinical and economic consequences were severe,” Dr Weycker said.
The researchers used an algorithm that combined the various codes for neutropenia, fever, and infection because there was no diagnostic code for febrile neutropenia. There were 25 total unique chemotherapy regimens for metastatic cancer of the breast, 26 for lung, 19 for colon/rectum, 10 for ovarian, and 4 for prostate.
The associated costs of febrile neutropenia were found to range from $16,000 to $19,000 per episode for most hospitalized patients. In addition, hospital mortality was 3.9% to 10.3%, depending on the type of disease.
Patients with lung cancer also had the highest rate of inpatient mortality, at 10.3%. It also most often required hospitalization (89% to 94%), with a mean length of stay of 1 week.
The study received funding support from Amgen.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
